Biology:Tucidinostat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Epidaza, Hiyasta |
| Other names | Chidamide, HBI-8000 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H19FN4O2 |
| Molar mass | 390.418 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tucidinostat (INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China.[1] It was also known as HBI-8000.[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.[3]
Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.[2][better source needed] In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.[4]
Tucidinostat is being researched as a treatment for pancreatic cancer.[5][6][7] However, it is not US FDA approved for the treatment of pancreatic cancer.
References
- ↑ Lowe, Derek (April 2015). "China's First Homegrown Pharma.". Seeking Alpha. http://seekingalpha.com/article/3055626-chinas-first-homegrown-pharma.
- ↑ 2.0 2.1 "Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China" (Press release). PR Newswire Association LLC.
- ↑ "HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai". PR Newswire Association LLC. February 2016. http://www.prnewswire.com/news-releases/huya-bioscience-international-grants-an-exclusive-license-for-hbi-8000-in-japan-and-other-asian-countries-to-eisai-300212563.html.
- ↑ "Marketing Approval of HBI-8000 (Tucidinostat) for Relapsed or Refractory ATLL Treatment in Japan". https://www.meiji.com/global/news/2021/pdf/210624_01.pdf.
- ↑ "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochemical and Biophysical Research Communications 434 (1): 95–101. April 2013. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
- ↑ "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews. Drug Discovery 14 (4): 225–6. April 2015. doi:10.1038/nrd4583. PMID 25829268.
- ↑ Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. https://www.wsj.com/articles/a-new-cancer-drug-made-in-china-1428004715.
 |  |
